Skip to main content

Progresses in the Drug Treatment of Chronic Cardiopulmonary Diseases

156kviews
Editorial19 May 2022
Editorial: Progresses in the Drug Treatment of Chronic Cardiopulmonary Diseases

We are delighted to announce the publication of the special issue with the topic ‘Progresses in the Drug Treatment of Chronic Cardiopulmonary Diseases’. 132 authors made their contributions to this issue and the editors finally assembled 18 full-length articles. The scale of accepted papers is wide covering from basic research to translational medicine and clinical studies. The content includes molecular mechanisms, meta-analysis, candidate compounds, metabolomics and bioinformatics. In our opinion these studies show advanced and useful information in this field, provide new insights into understanding of pathological mechanisms or identification of new therapeutical targets in Chronic Cardiopulmonary Diseases (CCD).

The authors paid attention to the pathophysiological mechanisms and biomarkers in challenging diseases including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension (PH) and pulmonary embolism (PE). For example, it is reported that Sirtuin (Sirt2) may participate in the development of IPF via regulating the drosophila mothers against decapentaplegic2/3 (Smad2/3) pathway [Gong et al]. Interferon regulatory factor 9 (IRF9) facilitates pulmonary artery smooth muscle cells proliferation by regulating prohibitin1 (PHB1) expression and protein kinase B (AKT) signaling pathway to affect mitochondrial function during the development of PH [Chen and colleagues]. MicroRNAs with pleiotropic effects have great potential as biomarkers and therapeutic targets for CCD [1-3]. Luo et al summarized the literature on miRNA functions in PE, suggesting that miRNA combined with traditional biomarkers or miRNA signatures generated from microchips may be a good predictive tool for PE occurrence and prognosis [Luo et al].

There are three articles summarizing the advances in PH, pulmonary thromboembolism (PTE) and chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSAS) overlap syndrome (OS). The nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PH [4-6], Tettey et al suggested that several new substances targeting on NO pathway show a promising potential to represent future alternatives [Tettey et al ]. The current knowledge indicates that COPD and OSAS patients may be at higher risk to develop the cardiovascular diseases. Collection and analysis of clinical data demonstrated that patients with OS possessed deteriorating baseline characteristics and an increased prevalence of cardiovascular diseases, among them the heart failure and PH, compared to the patients with COPD or OSAS alone [Tang and colleagues]. This is a clear reminder for clinicians to be alerted that OS patients have elevated risk of cardiovascular diseases and that early detection and adequate treatment are crucial for these individuals. Furthermore, it is known that PTE is an important cause of death in the context of cardiovascular diseases [7-9]. Following this line, Cao et al emphasized an overlooked condition, in situ pulmonary artery thrombosis and compared the risk factors, the common and specific pathogenic mechanisms underlying PTE, in situ pulmonary artery thrombosis, and chronic thromboembolic pulmonary hypertension (CTEPH), coining a new concept of pulmonary artery thrombotic disease and facilitating our understanding of pathogenesis, differential diagnosis, and personalised therapeutics of the three pulmonary artery thrombotic diseases [Cao et al ].

Metabolomics and bioinformatics are increasingly used approaches to identify the differential features between the states of health and disease [10-14]. Scientists from China, Netherlands, Switzerland and Germany together identified a metabolic profile that distinguished pulmonary artery smooth muscle cells from hypoxia-treated and control groups. This project discovered six hypoxia-induced metabolism associated hub genes in response to hypoxia [He and colleagues], which would lead to the better understanding of the profound molecular mechanisms in hypoxic PH and provide valuable clues to researchers who would follow these emerging genes in the future. Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) related gene sets were obtained through text mining by Tan et al. Furthermore, the intersection of gene sets was analyzed for functional enrichment through the DAVID and the STRING was used for the determination of the protein-protein interaction network of the overlapping genes and the significant gene modules. As the outcome, the enriched candidate genes were finally analyzed by Drug Gene Interaction database to find thirteen drugs targeting six genes which may potentially result in beneficial therapeutic effects against the severe disease, such as CTD-PAH [Tan et al].

Meta-analysis is still popular approach with regard to the clinical research of CCD, especially for assessment of the therapeutical effects or adverse events [15]. Articles discuss the role of inhaled corticosteroids (ICSs) and anti-interleukin-5 (IL-5) therapies in COPD [Chen, Sun et al][Zhang and colleagues]. In addition, clinical practice of sodium-glucose cotransporter 2 inhibitors (SGLT2is) is summarized with regard to the prevention of cardiovascular and respiratory dysfunctions [Yin et al] [16]. Some articles discuss compounds derived from plant extracts or medicinal chemistry research as novel potential treatments for CCD. For example, magnolol isolated from Magnolia Officinalis, Luteolin, Naringin usually extracted from tomatoes and citrus fruits and Sanguinarine, a benzophenanthridine alkaloid obtained primarily from the bloodroot plant were investigated in several pre-clinical experimental models of PH and right ventricle hypertrophy [Fu et al] [Zuo and colleagues] [Wu et al] [Fan and colleagues]. Results of these studies strongly suggested the promising pharmacological effects and revealed the underlying mechanisms of above mentioned natural compounds. One study also indicated the new clinical application of Xuezhikang, an extract of cholestin, which consists of lovastatin, phytosterols and isoflavones and it was previously used to reduce the serum lipid concentrations. Results showed the potential therapeutic effect of Xuezhikang on PH patients with low serum high-density lipoprotein cholesterol (HDL-C) levels [Cao, Sun and colleagues]. In the past, we became aware of the existence of significant limitations with regard to the monotherapy, and subsequently the clinical drug combinations were continuously investigated [17-19]. Following this paradigm, Shi et al found that therapy with rapamycin and low dose imatinib together achieved more beneficial effects as compared to the respective monotherapies in order to prevent the PH development [Shi et al]. Importantly, new compound and novel therapeutical strategy were developed by Li et al, this compound is HLQ2g which was designed to share the structure of Riociguat and also harbor the anti-fibrosis unit [Li et al]. Basically, it consists of pyrazolpyridine ring (anti-fibrosis functional group) and pyrimidine ring (stimulating soluble guanylate cyclase (sGC) functional group) [20]. Bifunctional HLQ2g might represent a new pharmacological strategy for PH.

In conclusion, it is clear that despite intensive research efforts to identify and develop new therapies over the past two decades, CCD remain a group of diseases characterized with high morbidity and mortality. The urgent clinical needs are still not properly addressed. Research in this field has become a hot and key venue, waiting for exciting new findings emerging from basic and clinical investigations into the pathophysiology and precise molecular pathobiology of CCD. We strongly call for more attention to CCD and the use of more cutting-edge technology to develop better treatment options.

1,694 views

ORIGINAL RESEARCH
18 March 2022
Text Mining-Based Drug Discovery for Connective Tissue Disease–Associated Pulmonary Arterial Hypertension
Jiang-Shan Tan, 3 more and Xiao-Jian Wang

3,089 views

5 citations

CORRECTION
5 January 2022
Corrigendum: The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook
Mingyao Luo, 5 more and Xin Li

1,554 views

2 citations

ORIGINAL RESEARCH
24 December 2021
Sanguinarine Reverses Pulmonary Vascular Remolding of Hypoxia-Induced PH via Survivin/HIF1α-Attenuating Kv Channels
Fenling Fan, 5 more and Yuliang Zou

3,933 views

10 citations

Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension
ORIGINAL RESEARCH
14 December 2021
Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension
Objective: Pulmonary hypertension (PH) associated with hypoxia and lung disease (Group 3) is the second most common form of PH and associated with increased morbidity and mortality. This study was aimed to identify hypoxia induced metabolism associated genes (MAGs) for better understanding of hypoxic PH. Methods: Rat pulmonary arterial smooth muscle cells (PASMCs) were isolated and cultured in normoxic or hypoxic condition for 24 h. Cells were harvested for liquid chromatography-mass spectrometry analysis. MAGs were then identified in Genecards. Transcriptomic data from lungs of hypoxic PH in mice/rats or of PH patients were accessed from GEO database or open-access online platform. Results: 36 altered metabolites and 1259 unique MAGs were identified in rat PASMCs under hypoxia. 38 differentially expressed MAGs in mouse lungs of hypoxic PH were revealed, with enrichment in multi-pathways including regulation of glucose metabolic process, which might be reversed by drugs such as blebbistatin. 5 differentially expressed MAGs were displayed in SMCs of Sugen 5416/hypoxia induced PH rats at the single cell resolution. Furthermore, 6 hub genes (Cat, Ephx1, Gpx3, Gstm4, Gstm5 and Gsto1) out of 42 unique hypoxia induced MAGs were identified. Higher Cat, Ephx1 and lower Gsto1 were displayed in mouse lungs under hypoxia (all P < 0.05), in consistent with the alteration in lungs of PH patients. The hub gene-based LASSO model can predict the occurrence of PH (AUC=0.90). Conclusions: Our findings revealed six hypoxia-induced metabolism associated hub genes, and shed some light on the molecular mechanism and therapeutic targets in hypoxic PH.

8,196 views

35 citations

ORIGINAL RESEARCH
20 December 2021
Effect of Xuezhikang Therapy on Expression of Pulmonary Hypertension Related miR-638 in Patients With Low HDL-C Levels
Ruihua Cao, 6 more and Ping Ye

2,337 views

1 citations

Inhibition of Sirt2 Alleviates Fibroblasts Activation and Pulmonary Fibrosis via Smad2/3 Pathway
Idiopathic pulmonary fibrosis (IPF) is a fatal disease with unknown cause and limited treatment options. Its mechanism needs to be further explored. Sirtuin2 (Sirt2), a nicotinamide adenine dinucleotide (NAD)-dependent deacetylase, has been proved to be involved in the fibrosis and inflammation in the liver, kidney and heart. In this study, we aimed to evaluate the role of Sirt2 in pulmonary fibrosis. We found that Sirt2 expression was upregulated in transforming growth factor-β1 (TGF-β1) treated human embryonic lung fibroblasts. Sirt2 inhibitor AGK2 or the knockdown of Sirt2 expression by targeting small interfering RNA (siRNA) suppressed the fibrogenic gene α-SMA and Fibronectin expression in TGF-β1 treated fibroblasts and primary lung fibroblasts derived from patients with IPF. In addition, Sirt2 inhibition suppresses the phosphorylation of Smad2/3. Co-immunoprecipitation showed that there is interaction between Sirt2 and Smad3 in the TGF-β1 treated lung fibroblasts. In bleomycin-induced pulmonary fibrosis in mice, AGK2 treatment significantly mitigated the degree of fibrosis and decreased the phosphorylation of Smad2/3. These data suggest that Sirt2 may participate in the development of IPF via regulating the Smad2/3 pathway. Inhibition of Sirt2 would provide a novel therapeutic strategy for this disease.

5,901 views

32 citations

ORIGINAL RESEARCH
1 December 2021
Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension
Yong-Jie Chen, 8 more and Xiang Wei

6,196 views

22 citations

REVIEW
12 November 2021
Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
Abraham Tettey, 2 more and Ying Li
Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even under treatment remains a big challenge attributed to the complex pathophysiology. Studies from clinical and non-clinical experiments have revealed that the nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PAH. Many of the essential drugs used in the management of PAH act on this pathway highlighting its significant role in PAH. Meanwhile, several novel compounds targeting on NO pathway exhibits great potential to become future therapy medications. Furthermore, the NO pathway is found to interact with other crucial pathways. Understanding such interactions could be helpful in the discovery of new drug that provide better clinical outcomes.

15,609 views

35 citations

ORIGINAL RESEARCH
2 November 2021
Monoclonal Antibodies Targeting IL-5 or IL-5Rα in Eosinophilic Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
Chuchu Zhang, 5 more and Jian Liu

6,403 views

20 citations

ORIGINAL RESEARCH
26 October 2021
Magnolol Attenuates Right Ventricular Hypertrophy and Fibrosis in Hypoxia-Induced Pulmonary Arterial Hypertensive Rats Through Inhibition of the JAK2/STAT3 Signaling Pathway
Minyi Fu, 5 more and Bin Liu

4,664 views

31 citations

MINI REVIEW
26 July 2021
Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
Dao-Gen Yin, 1 more and Xue-Yan Duan

4,309 views

22 citations

REVIEW
19 October 2021
The Function of microRNAs in Pulmonary Embolism: Review and Research Outlook
Mingyao Luo, 5 more and Xin Li

4,684 views

8 citations

ORIGINAL RESEARCH
1 October 2021
Novel Pyrazolo[3,4-b] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway
Lijun Li, 7 more and Xiaohui Li

3,111 views

13 citations

Pulmonary thromboembolism (PTE) is the third leading cause of death in cardiovascular diseases. PTE is believed to be caused by thrombi detached from deep veins of lower extremities. The thrombi travel with systemic circulation to the lung and block pulmonary arteries, leading to sudden disruption of hemodynamics and blood gas exchange. However, this concept has recently been challenged by accumulating evidence demonstrating that de novo thrombosis may be formed in pulmonary arteries without deep venous thrombosis. On the other hand, chronic thromboembolic pulmonary hypertension (CTEPH), a subtype of pulmonary hypertension, could have different pathogenesis than traditional PTE. Therefore, this article summarized and compared the risk factors, the common and specific pathogenic mechanisms underlying PTE, in situ pulmonary artery thrombosis, and CTEPH at molecular and cellular levels, and suggested the therapeutic strategies to these diseases, aiming to facilitate understanding of pathogenesis, differential diagnosis, and precision therapeutics of the three pulmonary artery thrombotic diseases.

19,579 views

51 citations

REVIEW
29 June 2021
Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials
Hong Chen, 5 more and Hao Yan
Inhaled Corticosteroids and the Pneumonia Risk in Patients With Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials
Background: Whether all types of inhaled corticosteroids (ICSs) would increase the pneumonia risk in patients with chronic obstructive pulmonary disease (COPD) remains controversial. We aimed to assess the association between ICSs treatment and pneumonia risk in COPD patients, and the impact of medication details and baseline characteristics of patients on the association. Methods: Four databases (PubMed, Embase, Cochrane Library, and Clinical Trials.gov) were searched to identify eligible randomized controlled trials (RCTs) comparing ICSs treatment with non-ICSs treatment on the pneumonia risk in COPD patients. Pooled results were calculated using Peto odds ratios (Peto ORs) with corresponding 95% confidence intervals (CIs). Results: A total of 59 RCTs enrolling 103,477 patients were analyzed. All types of ICSs significantly increased the pneumonia risk (Peto OR, 1.43; 95% CI, 1.34-1.53). Subgroup analysis showed that there was a dose-response relationship between ICSs treatment and pneumonia risk (low-dose: Peto OR, 1.33; 95% CI, 1.22-1.45; medium-dose: Peto OR, 1.50; 95% CI, 1.28-1.76; and high-dose: Peto OR, 1.64; 95% CI, 1.45-1.85). Subgroup analyses based on treatment durations and baseline characteristics (severity, age, and body mass index) of patients were consistant with the above results. Subgroup analysis based on severity of pneumonia showed that fluticasone (Peto OR, 1.75; 95% CI, 1.44-2.14) increased the risk of serious pneumonia, while budesonide and beclomethasone did not. Conclusions: ICSs treatment significantly increased the risk of pneumonia in COPD patients. There was a dose-response relationship between ICSs treatment and pneumonia risk. The pneumonia risk was related with COPD severity.

13,533 views

40 citations

ORIGINAL RESEARCH
15 April 2021
Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway
Wanyun Zuo, 8 more and Qiming Liu
Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway
Luteolin is a flavonoid compound with a variety of pharmacological effects. In this study, we explored the effects of luteolin improving monocrotaline (MCT) induced rat pulmonary arterial hypertension (PAH) and underlying mechanisms. We constructed a rat PAH model through MCT injection. In this model, luteolin improved pulmonary vascular remodeling and right ventricular hypertrophy, meanwhile, luteolin could inhibit the proliferation and migration of pulmonary artery smooth muscle cells induced by platelet-derived growth factor-BB (PDGF-BB) in a dose-dependent manner. Moreover, our results showed that luteolin could downregulate the expression of LATS1 and YAP, decrease YAP nuclear localization, reduce the expression of PI3K, and thereby restrain the phosphorylation of AKT induced by PDGF-BB. In conclusion, luteolin exerts protective effects against experimental PAH, which are partly mediated through suppressing HIPPO-YAP/PI3K/AKT signaling pathway. Therefore, luteolin might become a promising candidate target medicine for PAH.

7,550 views

81 citations